NCT01407380 is a Phase 1 clinical trial of PWT33597 mesylate in Malignancies, sponsored by Pathway Therapeutics, Inc..

Who is sponsoring NCT01407380?

NCT01407380 is sponsored by Pathway Therapeutics, Inc..

What drugs are being tested in NCT01407380?

Interventions in NCT01407380: PWT33597 mesylate.

What condition does NCT01407380 study?

NCT01407380 studies Malignancies.

Is NCT01407380 still recruiting?

NCT01407380 is currently completed. Last updated 23 October 2012.

Last reviewed 2012-10-23 · How we verify

NCT01407380

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Phase 1, Open-Label, Dose-Escalation Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Effects of Orally Administered PWT33597 Mesylate in Subjects With Advanced Malignancies

Completed Phase 1 Last updated 23 October 2012

What this trial tests

Phase 1 trial testing PWT33597 mesylate in Malignancies in 22 participants. Completed in 1 September 2012.

Timeline

1 June 2011

Primary endpoint
1 August 2012

1 September 2012

Quick facts

Lead sponsor	Pathway Therapeutics, Inc.
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	22
Start date	1 June 2011
Primary completion	1 August 2012
Estimated completion	1 September 2012
Sites	4 locations across United States

Drugs / interventions tested

PWT33597 mesylate — full drug profile →

Conditions studied

Malignancies — all drugs for Malignancies →

Sponsor

Pathway Therapeutics, Inc. — full company profile →

Who can join

18 and older, any sex, with Malignancies. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Number of patients with adverse events
Time frame: 2 years

Sponsor's own description

This is a Phase 1 study evaluating the safety, pharmacokinetics, pharmacodynamics, and clinical effects of orally administered PWT33597 mesylate in subjects with advanced malignancies.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

PI3K/Akt/mTOR Signaling Pathway as a Target for Colorectal Cancer Treatment.
Leiphrakpam PD, Are C. · · 2024 · cited 105× · PMID 38542151 · DOI 10.3390/ijms25063178
Targeting the RAS oncogene.
Takashima A, Faller DV. · · 2013 · cited 95× · PMID 23360111 · DOI 10.1517/14728222.2013.764990
Targeting PI3K family with small-molecule inhibitors in cancer therapy: current clinical status and future directions.
Li H, Wen X, Ren Y, Fan Z, et al · · 2024 · cited 57× · PMID 39127670 · DOI 10.1186/s12943-024-02072-1

Verify or expand the search:

Other recruiting trials for Malignancies

Currently open trials in the same condition.

NCT06703853 — Identifying Tissue-of-origin in Transplant Patients and Patients with Malignancies. · active not recruiting
NCT05929495 — Phase 2, Open-label, Single-arm Study on the Use of Metformin as Adjunctive Therapy in High-grade Glioma · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01407380 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Pathway Therapeutics, Inc.
Last refreshed: 23 October 2012

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01407380.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing